Skip to main content

Table 1 Baseline characteristics

From: Real-world experience of angiotensin receptor/neprilysin inhibitor (ARNI) usage in Thailand: a single-center, retrospective analysis

  ARNI
n = 87
Standard treatment
n = 100
P-value
Age (mean ± SD) 63.30 ± 15.03 59.14 ± 18.68 0.098
Male (%) 59 (67.8) 61 (61.0) 0.330
BMI (mean ± SD) 24.9 ± 6.49 22.1 ± 7.30 0.006
Baseline LVEF (mean ± SD) 26.3 ± 8.38 28.50 ± 8.07 0.078
Baseline SBP (mean ± SD) 114.3 ± 18.46 119.3 ± 19.54 0.073
Baseline DBP (mean ± SD) 69.3 ± 9.70 71.8 ± 9.91 0.085
Comorbidities (%)
 Hypertension 52 (59.8) 46 (46.0) 0.060
 Diabetes 38 (43.7) 43 (43.0) 0.926
 Dyslipidemia 34 (39.1) 42 (42.0) 0.685
 Coronary artery disease 35 (40.2) 41 (41.0) 0.915
 Atrial fibrillation 27 (31.0) 27 (27.0) 0.544
 Mitral regurgitation 21 (24.1) 22 (22.0) 0.729
 Chronic kidney disease 16 (18.4) 32 (32.0) 0.034
Type of cardiomyopathy (%)
 Dilated cardiomyopathy 55 (63.2) 46 (46.0) 0.018
 Ischemic cardiomyopathy 27 (31.0) 41 (41.0) 0.158
NYHA classification (%)*
 Class I 12 (13.8) 22 (22.0) 0.732
 Class II 56 (64.4)   
 Class III 9 (10.3) 10 (10.0)  
 Class IV 1 (1.2) 2 (2.0)  
Intracardiac devices (%)
 AICD 23 (26.4) 24 (24.0) 0.702
 CRT 23 (26.4) 13 (13.0) 0.020
Baseline HF medication (%)
 Beta-blockers 81 (93.1) 92 (92.0) 0.775
 MRA 65 (74.7) 68 (68.0) 0.312
 Ivabradine 12 (13.8) 3 (3.0) 0.007
 Digoxin 11 (12.6) 6 (6.0) 0.115
 Diuretics 59 (67.8) 72 (72.0) 0.533
  1. AICD = automated implantable cardioverter defibrillator, ARNI = angiotensin receptor/ neprilysin inhibitor, BMI = body mass index, CRT = cardiac resynchronization therapy, DBP = diastolic blood pressure, HF = heart failure, LVEF = left ventricular ejection fraction, MRA = mineralocorticoid receptor antagonist, NYHA = New York Heart Association, SBP = systolic blood pressure, SD = standard deviation
  2. *Baseline NYHA functional class was reported in 78 and 94 patients in ARNI group and standard treatment group, respectively